England approves Avastin for women with advanced cervical cancer

Pinterest LinkedIn Tumblr +

woman_cervical cancer_oncologynewscomau
Source: The Guardian – Denis Campbell.

NHS England to be pioneer in making available drug that could extend lives of cervical cancer patients by up to four months

Women in England who are dying of cervical cancer are to receive a drug that could extend their lives by as much as four months.

Women with advanced cervical cancer will be able to get Avastin, which is also known as bevacizumab, after NHS England decided to fund courses of treatment with it for such patients, at the cost of about £23,295 per person.

The cash will come out of the Department of Health’s £200m-a-year Cancer Drugs Fund, which was started by the coalition to enable patients to access drugs which the National Institute for Health and Care Excellence (Nice), the government’s official advisers, judges to be not cost-effective.

blood vessels oncologynewscomau

Avastin is already used to treat advanced forms of breast, lung, bowel, ovarian and kidney cancer. NHS England has now included it on the Cancer Drugs Fund’s list of approved medications for use by cervical cancer sufferers who are near the end of their lives.

Its decision means England is the first country in the world to make the drug available for such patients, it said.

Robert Music, chief executive of Jo’s Cervical Cancer Trust, said the drug’s inclusion on the list was “very positive as for women who receive a late-stage diagnosis of cervical cancer, the prognosis can often be poor.

“When this is the case, any extra time that can be provided through new drugs becomes extremely valuable. We hope this will result in extended survival without impacting on quality of life for those facing non-curative treatment,” he added…Read the full story


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.